Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.



home / articles / NVO - Using Ozempic Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery European Medicines Agency Issues Advisory | Benzinga


NVO - Using Ozempic Zepbound Or Other Weight Loss Drugs? Inform Doctors Before Anesthesia Or Surgery European Medicines Agency Issues Advisory | Benzinga

On Friday, the European Medicines Agency (EMA) warned patients using weight-loss drugs, such as Novo Nordisk A/S’s (NYSE:NVO) Wegovy, to inform their doctors before general anesthesia or deep sedation surgery.

This recommendation stems from potential respiratory complications linked to these medications.

Related: Only 25% Patients Stick With Novo Nordisk’s Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient.

Weight-loss drugs like Wegovy and Eli Lilly And Co’s (NYSE:LLY) Zepbound and Mounjaro belong to a class known as GLP-1 receptor agonists, which slow the emptying ...

Full story available on Benzinga.com

Stock Information

Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Website: novonordisk.com

Menu

NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...